Items Tagged ‘B-cell’

August 22nd, 2017

The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia

By

Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express the CD22 antigen. Acute lymphoblastic leukemia comprises approximately 25% of cancer diagnoses among children under 15 years old and is the most common childhood cancer in the US1. Effective treatment options for patients with r/r […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, B-cell, Besponsa, Inotuzumab, Leukemia, News, ozogamicin, targeted therapy